Medications Affecting Cardiac Rhythm

Quinidine (Class IA Antiarrhythmics)

• Classification and Identification

  • Class/Group: Class IA sodium-channel blocker with potassium-channel effects.

  • Prototype: Quinidine.

  • Principal Educational Concept: Quinidine slows cardiac conduction and prolongs both repolarization and the $QT$ interval. Monitoring is critical for torsades de pointes, cinchonism, diarrhea, and numerous drug interactions.

• Therapeutic Indications

  • The medication is utilized for selected atrial or ventricular dysrhythmias when safer alternative options are deemed inappropriate.

  • It is effective in suppressing abnormal automaticity and re-entry circuits.

  • Due to the risks of proarrhythmia and significant toxicity, it requires meticulous patient selection and monitoring.

• Mechanism of Action

  • The drug works by blocking fast sodium channels, which results in the slowing of phase-$0$ depolarization and overall conduction.

  • It also blocks potassium channels, which prolongs the action potential and the $QT$ interval.

  • Quinidine possesses anticholinergic effects, which may inadvertently increase Atrioventricular ($AV$) conduction in specific atrial rhythms.

• Side Effects and Rationales

  • Common gastrointestinal and neurological effects include diarrhea, nausea, vomiting, headache, and dizziness.

  • Cinchonism: A specific toxicity syndrome characterized by tinnitus, hearing changes, blurred vision, headache, and confusion.

  • Vasodilation: Hypotension can occur as a result of peripheral vasodilation and direct cardiac effects.

• Serious Adverse Reactions

  • Cardiac Risks: $QT$ prolongation can lead to torsades de pointes and sudden cardiac death. The drug may worsen dysrhythmias and has been associated with increased mortality in certain non-life-threatening rhythm scenarios.

  • Hematologic/Immunologic: Thrombocytopenia, hemolysis, or severe hypersensitivity reactions may occur.

• Nursing and Clinical Focus

  • Monitoring: Continuous assessment of the ECG is required, specifically focusing on $QT$ and $QRS$ intervals, heart rate, and Blood Pressure ($BP$).

  • Lab Values: Regularly monitor serum levels of potassium ($K^+$), magnesium ($Mg^{2+}$), and calcium ($Ca^{2+}$). Correct any electrolyte abnormalities promptly.

  • Patient Reporting: Instruct patients to report tinnitus, changes in hearing or vision, severe diarrhea, fainting, or new palpitations.

  • Interactions: Review medications carefully; notably, quinidine can increase digoxin levels. Avoid concurrent use with other $QT$-prolonging drugs when possible.

Lidocaine (Xylocaine) - Antiarrhythmic Use (Class IB)

• Classification and Identification

  • Class/Group: Class IB sodium-channel blocker; administered intravenously ($IV$) as a ventricular antiarrhythmic.

  • Prototype: Lidocaine.

  • Principal Educational Concept: This is an $IV$ medication for acute ventricular dysrhythmias. Early toxicity is signaled by mouth numbness, a metallic taste, tinnitus, confusion, tremors, and seizures.

• Therapeutic Indications

  • Administered $IV$ for acute, life-threatening ventricular dysrhythmias, particularly those occurring in ischemic cardiac tissue.

  • It is capable of suppressing ventricular ectopy without causing significant slowing in normal atrial tissue.

• Mechanism of Action

  • Lidocaine blocks fast sodium channels primarily within depolarized or ischemic ventricular tissue.

  • It decreases abnormal ventricular automaticity and conduction.

  • The drug has a rapid onset of action and is metabolized by the liver.

• Side Effects and Rationales

  • Neurological effects include drowsiness, dizziness, paresthesias, or mild confusion.

  • Systemic effects include nausea, and as blood levels rise, speech or coordination may become impaired.

  • Cardiovascular effects during $IV$ therapy may include hypotension or bradycardia.

• Serious Adverse Reactions

  • Central Nervous System (CNS) Toxicity: Symptoms can progress from perioral numbness, metallic taste, and tinnitus to seizures, coma, and respiratory arrest.

  • Cardiovascular Collapse: Severe bradycardia, heart block, or new ventricular dysrhythmias may occur.

  • Accumulation Risks: Toxicity is more likely in patients with liver disease, heart failure, those receiving prolonged infusions, or older adults.

• Nursing and Clinical Focus

  • Administration: Use an infusion pump for delivery.

  • Assessment: Maintain continuous ECG, $BP$, respiratory, and neurologic monitoring. If early signs of toxicity appear, stop the infusion and notify the provider immediately.

  • Dosing: Dose reductions may be necessary for patients with liver disease, low cardiac output, or advanced age.

  • Safety: Ensure that antiarrhythmic $IV$ products are not confused with local-anesthetic products or different concentrations.

Propafenone (Rythmol) (Class IC)

• Classification and Identification

  • Class/Group: Class IC sodium-channel blocker with additional beta-blocking activity.

  • Prototype: Propafenone.

  • Principal Educational Concept: This drug strongly slows conduction and may induce new dysrhythmias. It should generally be avoided in patients with structural heart disease, heart failure, or significant ischemic disease.

• Therapeutic Indications

  • Used for the management of selected Atrial Fibrillation ($AFib$), Atrial Flutter, or Supraventricular Tachycardia ($SVT$) in carefully screened patients.

  • Assists in maintaining sinus rhythm by slowing rapid conduction.

• Mechanism of Action

  • Strongly blocks fast sodium channels, slowing conduction through both atrial and ventricular tissues.

  • Possesses mild beta-blocking activity.

  • Interrupts re-entry circuits, though it carries the risk of making conduction dangerously slow.

• Side Effects and Rationales

  • Common complaints include a metallic or unusual taste, dizziness, nausea, constipation, and fatigue.

  • Cardiac signs include bradycardia or mild $QRS$ widening.

  • Beta-blocking effects may lead to weakness or bronchospasm.

• Serious Adverse Reactions

  • Proarrhythmia: Can cause ventricular tachycardia, heart block, or sudden death.

  • Heart Failure: Negative inotropic effects can worsen existing heart failure.

  • Respiratory: Bronchospasm can occur in susceptible populations.

• Nursing and Clinical Focus

  • ECG Monitoring: Obtain baseline and follow-up ECGs to monitor $QRS$, $PR$ interval, rhythm, heart rate, and $BP$.

  • Contraindications: Avoid use in significant structural heart disease unless explicitly directed by a specialist.

  • Metabolism: Review liver function and potential interactions involving $CYP2D6$ and $CYP3A$ pathways.

  • Patient Teaching: Report fainting, new palpitations, chest pain, wheezing, or worsening shortness of breath ($SOB$).

Flecainide (Tambocor) (Class IC)

• Classification and Identification

  • Class/Group: Class IC sodium-channel blocker.

  • Prototype: Flecainide.

  • Principal Educational Concept: A strong conduction-slowing drug for selected atrial rhythms. It is avoided after Myocardial Infarction ($MI$) or in significant structural heart disease due to increased mortality and proarrhythmia risk.

• Therapeutic Indications

  • Used to prevent paroxysmal $AFib$, atrial flutter, or $SVT$.

  • May be utilized for serious ventricular dysrhythmias under specialist supervision.

• Mechanism of Action

  • Strongly blocks fast sodium channels, slowing conduction heart-wide.

  • Causes lengthening of the $PR$ and $QRS$ intervals.

  • Interrupts re-entry pathways; however, excessive slowing may create new rhythm disturbances.

• Side Effects and Rationales

  • Common effects include dizziness, headache, nausea, and visual disturbances such as blurring or spots in the vision.

  • Patients may report palpitations or fatigue.

  • ECG will show mild conduction slowing.

• Serious Adverse Reactions

  • Mortality: Historical data shows increased mortality when Class IC drugs were used post-$MI$ for non-life-threatening ventricular ectopy.

  • Cardiac Function: Can cause ventricular proarrhythmia, heart block, or sudden death. Negative inotropic effects can exacerbate heart failure.

• Nursing and Clinical Focus

  • Assessment: Monitor ECG, $PR$ and $QRS$ intervals, rhythm, heart rate, and $BP$.

  • Screening: Confirm the absence of significant structural or ischemic heart disease before administration unless directed by a specialist.

  • Organ Function: Monitor renal and liver function, as drug accumulation increases the risk of toxicity.

Amiodarone (Cordarone / Pacerone) (Class III)

• Classification and Identification

  • Class/Group: Class III antiarrhythmic with complex effects blocking potassium, sodium, calcium, and beta-receptors.

  • Prototype: Amiodarone.

  • Principal Educational Concept: highly effective but also highly toxic. Requires monitoring of the lungs, liver, thyroid, eyes, ECG, and skin, along with major drug interactions.

• Therapeutic Indications

  • Used for recurrent life-threatening Ventricular Fibrillation ($VFib$) or unstable Ventricular Tachycardia ($VT$).

  • Used under specialist guidance for certain atrial dysrhythmias when other treatments fail.

• Mechanism of Action

  • Primarily blocks potassium channels, prolonging repolarization and the refractory periods.

  • Additionally blocks sodium and calcium channels and provides beta-blocking effects.

  • Results in decreased automaticity and $AV$ conduction.

• Side Effects and Rationales

  • General: Bradycardia, nausea, fatigue, and tremors are common.

  • Dermatologic/Ocular: Photosensitivity and corneal deposits may occur. Long-term exposure can lead to a distinct blue-gray skin discoloration.

  • Pharmacokinetics: The drug has an extremely long half-life, meaning effects and interactions can persist for weeks or months after discontinuation.

• Serious Adverse Reactions

  • Systemic Toxicity: Pulmonary pneumonitis or fibrosis, severe liver injury, thyroid dysfunction (hypo- or hyperthyroidism), and optic neuropathy can be life-threatening.

  • Cardiac: Bradycardia, heart block, or proarrhythmia.

  • Interactions: Amiodarone significantly raises levels of many drugs, notably warfarin and digoxin.

• Nursing and Clinical Focus

  • Diagnostics: Obtain/monitor ECG, chest assessments (imaging or Pulmonary Function Tests/$PFTs$), liver function tests ($LFTs$), thyroid tests, and eye exams.

  • Patient Teaching: Report new cough, dyspnea ($SOB$), jaundice, vision changes, fainting, or significant changes in weight/temperature tolerance.

  • Lifestyle: Use sun protection and strictly avoid grapefruit products.

  • Medication Management: Review all medications for interactions; warfarin and digoxin doses often require downward adjustment.

Adenosine (Adenocard) (Class VI / Miscellaneous)

• Classification and Identification

  • Class/Group: Adenosine-receptor agonist; transient $AV$-nodal blocker.

  • Prototype: Adenosine.

  • Principal Educational Concept: Given as a rapid $IV$ push to briefly block the $AV$ node and terminate regular narrow-complex $SVT$. Expected effects include flushing, chest pressure, and a brief pause in rhythm.

• Therapeutic Indications

  • Rapidly converts specific regular supraventricular tachycardias to sinus rhythm.

  • Used diagnostically to reveal underlying atrial activity during narrow-complex tachycardia.

  • The ultra-short half-life (less than $10\,seconds$) ensures effects conclude rapidly.

• Mechanism of Action

  • Activates adenosine receptors in the $AV$ node.

  • Induces potassium efflux from cells and decreases calcium entry, resulting in a brief, transient $AV$ block.

  • This interrupts the re-entry circuit, allowing the sinus node to resume control.

• Side Effects and Rationales

  • Common but transient symptoms include flushing, chest pressure, dyspnea, nausea, headache, and a "sense of doom."

  • Expected Rhythm: A short period of bradycardia or asystole is expected on the cardiac monitor immediately following administration.

• Serious Adverse Reactions

  • Cardiac: Prolonged asystole, ventricular dysrhythmias, or severe hypotension.

  • Respiratory: Bronchospasm, which can be dangerous in patients with asthma or reactive-airway disease.

  • Other: Seizures or the development of atrial fibrillation (dangerous if an accessory pathway exists).

• Nursing and Clinical Focus

  • Administration Technique: Must be given as a very rapid $IV$ bolus through the port closest to the patient, immediately followed by a rapid saline flush.

  • Safety: Use continuous ECG monitoring and ensure resuscitation equipment is immediately available.

  • Patient Prep: Warn the patient about the brief chest pressure, flushing, and the sensation that the heart has stopped.

  • Interactions: Caffeine and theophylline can reduce the drug's effectiveness; dipyridamole can increase the effect.

Atropine (Atropen) (Anticholinergic)

• Classification and Identification

  • Class/Group: Muscarinic anticholinergic; vagolytic medication.

  • Prototype: Atropine.

  • Principal Educational Concept: Blocks vagal slowing to increase heart rate in symptomatic bradycardia. Monitor for tachycardia, urinary retention, confusion, dry mouth, and blurred vision.

• Therapeutic Indications

  • Used for the treatment of symptomatic bradycardia and in specific cholinergic poisoning cases.

  • Temporarily improves Sinoatrial ($SA$) node firing and $AV$ node conduction.

  • Serves as a bridge while preparing for transcutaneous pacing or other definitive therapies.

• Mechanism of Action

  • Atropine competitively blocks muscarinic acetylcholine receptors.

  • This decreases the parasympathetic (vagal) effects on the heart, thereby increasing heart rate and $AV$ conduction.

• Side Effects and Rationales

  • Anticholinergic Effects: Dry mouth, blurred vision, photophobia, constipation, and urinary retention.

  • Cardiac: Tachycardia and palpitations are expected results of the drug's action.

  • Neurological: Older adults are at higher risk for developing confusion or agitation.

• Serious Adverse Reactions

  • Cardiac Stress: Severe tachyarrhythmias or myocardial ischemia can be induced.

  • Thermoregulation: Hyperthermia may occur due to reduced sweating.

  • Acute Triggers: Can trigger acute urinary retention or angle-closure glaucoma in susceptible patients.

• Nursing and Clinical Focus

  • Assessment: Monitor ECG, heart rate, $BP$, mental status, body temperature, and urine output.

  • Contingency: Prepare transcutaneous pacing if the medication is ineffective.

  • Precautions: Use with extreme caution in patients with glaucoma, urinary obstruction, Gastrointestinal ($GI$) obstruction, and in the elderly.

  • Reporting: Patients/staff should report chest pain, severe confusion, inability to urinate, or a very rapid/irregular pulse.